Dr. Ami Desai is not attending the meeting; thus, this waiver is null and void.

U.S. FOOD & DRUG ADMINISTRATION

Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: **Ami Desai, M.D., MSCE**

Committee: **Oncologic Drugs Advisory Committee**

Meeting Date: **October 4, 2023**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On October 4, 2023, the committee will discuss new drug application (NDA) 215500, for eflornithine tablets, submitted by USWM, LLC (doing business as U.S. WorldMeds). The proposed indication (use) for this product is to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma who have completed multiagent, multimodality therapy.

Type of Interest	Nature	Magnitude
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
Contracts/grants	Employer's research involving eflornithine, funded by Children's Oncology Group	$0-$ (b) (4) per patient and estimated $10,000 - $20,000 in total to University of Chicago. At the writing of this waiver, University of Chicago has accrued (b) (4).
Contracts/grants	Employer's research involving eflornithine, funded by New Approaches to Neuroblastoma Therapy Consortium	All funding received

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/S/
Signature

9/18/2023
Date

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov